Literature DB >> 10816491

A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture.

E D Franke1, A Sette, J Sacci, S Southwood, G Corradin, S L Hoffman.   

Abstract

Previous studies indicated that the Plasmodium yoelii circumsporozoite protein (PyCSP) 57-70 region elicits T cells capable of eliminating infected hepatocytes in vitro. Herein, we report that the PyCSP58-67 sequence contains an H-2(d) binding motif, which binds purified K(d) molecules in vitro with low affinity (3, 267 nM) and encodes an H-2(d)-restricted cytotoxic T lymphocyte (CTL) epitope. Immunization of BALB/c mice with three doses of a multiple antigen peptide (MAP) construct containing four branches of amino acids 57 to 70 linked to a lysine-glycine core [MAP4(PyCSP57-70)] and Lipofectin as the adjuvant induced both T-cell proliferation and a peptide-specific CTL response that was PyCSP59-67 specific, H-2(d) restricted, and CD8(+) T cell dependent. Immunization with either DNA encoding the PyCSP or irradiated sporozoites demonstrated that this CTL epitope is subdominant since it is not recognized in the context of whole CSP immunization. The biological relevance of this CTL response was underlined by the demonstration that it could mediate genetically restricted, CD8(+)- and nitric-oxide-dependent elimination of infected hepatocytes in vitro, as well as partial protection of BALB/c mice against sporozoite challenge. These findings indicate that subdominant epitopes with low major histocompatibility complex affinity can be used to engineer epitope-based vaccines and have implications for the selection of epitopes for subunit-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816491      PMCID: PMC97612          DOI: 10.1128/IAI.68.6.3403-3411.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides.

Authors:  S Buus; A Sette; S M Colon; C Miles; H M Grey
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

2.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins.

Authors:  W M Kast; R M Brandt; J Sidney; J W Drijfhout; R T Kubo; H M Grey; C J Melief; A Sette
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

3.  Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12.

Authors:  G Eberl; B Kessler; L P Eberl; M J Brunda; D Valmori; G Corradin
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

4.  Nomenclature for factors of the HLA system, 1994.

Authors:  J G Bodmer; S G Marsh; E D Albert; W F Bodmer; B Dupont; H A Erlich; B Mach; W R Mayr; P Parham; T Sasazuki
Journal:  Tissue Antigens       Date:  1994-07

5.  Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes.

Authors:  N D Pacheco; C P Strome; F Mitchell; M P Bawden; R L Beaudoin
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

6.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

Authors:  Y Kawakami; S Eliyahu; C Jennings; K Sakaguchi; X Kang; S Southwood; P F Robbins; A Sette; E Appella; S A Rosenberg
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

7.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

Authors:  M Sedegah; R Hedstrom; P Hobart; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody.

Authors:  Y Charoenvit; S Mellouk; M Sedegah; T Toyoshima; M F Leef; P De la Vega; R L Beaudoin; M Aikawa; V Fallarme; S L Hoffman
Journal:  Exp Parasitol       Date:  1995-05       Impact factor: 2.011

9.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Authors:  S L Topalian; M I Gonzales; M Parkhurst; Y F Li; S Southwood; A Sette; S A Rosenberg; P F Robbins
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  8 in total

1.  Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Authors:  Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

2.  Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.

Authors:  Emily K Forbes; Sumi Biswas; Katharine A Collins; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2011-08-29       Impact factor: 5.422

3.  Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model.

Authors:  Simon H Apte; Penny L Groves; Mariusz Skwarczynski; Yoshio Fujita; Chenghung Chang; Istvan Toth; Denise L Doolan
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

4.  Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells.

Authors:  Wen Su; Wenwei Zhong; Yanjie Zhang; Zhenwei Xia
Journal:  BMC Immunol       Date:  2012-07-06       Impact factor: 3.615

5.  Isolation and Characterization of Vaccine Candidate Genes Including CSP and MSP1 in Plasmodium yoelii.

Authors:  Seon-Hee Kim; Young-An Bae; Ju-Young Seoh; Hyun-Jong Yang
Journal:  Korean J Parasitol       Date:  2017-06-30       Impact factor: 1.341

6.  Identification of Plasmodium falciparum proteoforms from liver stage models.

Authors:  Benjamin Winer; Kimberly A Edgel; Xiaoyan Zou; Julie Sellau; Sri Hadiwidjojo; Lindsey S Garver; Christin E McDonough; Neil L Kelleher; Paul M Thomas; Eileen Villasante; Alexander Ploss; Vincent R Gerbasi
Journal:  Malar J       Date:  2020-01-07       Impact factor: 2.979

7.  A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria.

Authors:  Frédéric Coutant; Raul Yusef Sanchez David; Tristan Félix; Aude Boulay; Laxmee Caleechurn; Philippe Souque; Catherine Thouvenot; Catherine Bourgouin; Anne-Sophie Beignon; Pierre Charneau
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

Review 8.  Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?

Authors:  Anne S De Groot; Leo Einck; Leonard Moise; Michael Chambers; John Ballantyne; Robert W Malone; Matthew Ardito; William Martin
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.